

Ortho RTi Announces Extension of Certain Early Warrants

/NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR RELEASE, PUBLICATION, DISTRIBUTION OR DISSEMINATION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES/

KIRKLAND, QC, April 25, 2019 /CNW/ - Ortho Regenerative Technologies Inc. (**CSE: ORTH**) ("**Ortho RTi**" or the "**Company**") announces the extension of the term of certain warrants of the Company (the "**Extended Warrants**") which were issued in connection with a private placement (the "**Private Placement**") closed in October 2017.

The Extended Warrants, representing an aggregate of 905,000 warrants, originally expired on April 29, 2019. The Company has requested and obtained from the CSE an exemption from the ten (10) trading days rule. Pursuant to the Warrant Term Extension, the expiry dates of the Warrants issued in conjunction with the Private Placement is extended for one (1) year from their original maturity date. All other terms of the Extended Warrants will remain unchanged.

About Ortho Regenerative Technologies Inc.

Ortho RTi is an emerging Orthopaedic and Sports Medicine biologics company dedicated to the development of novel therapeutic soft tissue repair technologies to dramatically improve the success rate of sports medicine surgeries. Our proprietary biopolymer has been specifically designed to increase the healing rates of sports related injuries to tendons, meniscus, ligaments and cartilage. The polymer can be directly placed into the site of injury by a surgeon during a routine operative procedure without significantly extending the time of the surgery and without further intervention. Considering the significant bioactivity and residency of our proprietary biopolymer, Ortho RTi continues to assess its potential for therapeutic uses outside of the soft tissue repair. Further information about Ortho RTi is available on the Company's website at www.orthorti.com and on SEDAR at www.sedar.com.

Forward-Looking Statements

This news release may contain certain forward-looking statements regarding the Company's expectations for future events. Such expectations are based on certain assumptions that are founded on currently available information. If these assumptions prove incorrect, actual results may differ materially from those contemplated by the forward-looking statements contained in this press release. Factors that could cause actual results to differ include, amongst others, uncertainty as to the final result and other risks. The Company disclaims any intention or obligation to publicly update or revise any forward- looking statements, whether as a result of new information, future events or otherwise, other than as required by security laws.

NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATIONS SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE

SOURCE Ortho Regenerative Technologies Inc.

View original content: <http://www.newswire.ca/en/releases/archive/April2019/25/c4222.html>

%SEDAR: 00037950E

For further information: Brent Norton MD, MBA, ICD.D, Chief Executive Officer, 514.782.0951,
norton@orthorti.com

CO: Ortho Regenerative Technologies Inc.

CNW 17:27e 25-APR-19